Immunotherapies that utilize PD-1/PD-L1 antibodies and CTLA-4 are currently undergoing clinical trials with some encouraging results.47 But the benefits seen in CRC have been limited to a few groups of patients with MSI-H tumors, which makes up only 3.5-17% of all CRCs.48,49 Therefore, a new therapeutic approach that does not only benefit a select group of CRC patients is highly desired. This evidence concerns the gene CTLA4 and colorectal carcinoma.